Medcura, Inc., a Riverdale, Md.-based commercial-stage medical device company, raised $7.4m in funding.
The financing includes the sale of Series A Preferred stock as well as common stock based, in part, from certain investors benefitting from a Maryland Investment Incentive Program.
The company intends to use the funds to expand its product line and develop its lead surgical candidate for clinical evaluation.
Led by Larry Tiffany, CEO, Medcura is a commercial-stage medical device company developing versatile hemostatic products for surgical, medical, and consumer applications. It is involved in the development and commercialization of a broad range of hemostatic and wound treatment products. These products include:
- Rapid-Seal® becoming a market leader in high-performance, antibacterial first aid;
- LifeFoam™ under development as a breakthrough device for internal traumatic and military injuries; and
- LifeGel™ under development for use during routine surgery.
These products all benefit from the company’s intellectual property estate, emergent FDA regulatory experience and continual expansion of its manufacturing capabilities.
FinSMEs
12/08/2021